HOME >> BIOLOGY >> NEWS
Double-trouble: Cells with duplicate genomes can trigger tumors

The idea that a failure of proper cell division produces genomic instability and promotes the development of cancer was first proposed by German biologist Theodor Boveri in 1915. The fact that tumor cells often have abnormal numbers of chromosomes supports this theory, and two papers published by Harvard Medical School researchers provide new, more direct evidence to support this.

David Pellman, Harvard Medical School associate professor of pediatrics at Dana-Farber Cancer Institute and Children's Hospital Boston, and colleagues tested the theory by blocking cell division in cells that also lack the tumor suppressor gene p53, to generate tetraploid cells - cells that contain a double quota of chromosomes. Compared to their diploid counterparts, which have a normal set of chromosomes, tetraploid cells were more prone to generate tumors in mice, and these tumors showed genomic instability similar to many human cancers.

Another study by Randall King, HMS assistant professor of cell biology, shows how tetraploid cells can arise. He shows that inaccurate segregation even of a single pair of chromosomes - an error that does occur randomly will halt cell division and produce tetraploid cells. Together, these papers lend experimental support to Boveri's ideas that errors in cell division contribute to the development of cancer.


'"/>

Contact: Leah Gourley
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
14-Oct-2005


Page: 1

Related biology news :

1. Cells take risks with their identities
2. Cells re-energize to come back from the brink of death
3. Need oxygen? Cells know how to spend and save
4. Cells selectively absorb short nanotubes
5. Cells use noise to make cell-fate decisions
6. Cells in the lung clear the air to prevent lung damage
7. Cells passed from mother to child during pregnancy live on and make insulin
8. Cells, dyes and videotape: Online scientific methods journal incorporates multimedia
9. Cells use mix-and-match approach to tailor regulation of genes
10. Cells in mucus from lungs of high-risk patients can predict tumor development
11. Double trouble: Cells with duplicate genomes can trigger tumors

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Double trouble Cells with duplicate genomes can trigger tumors

(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
(Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
(Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
(Date:3/25/2015)... CA (PRWEB) March 25, 2015 ... for Novel Mechanism of Action in Neuromuscular Diseases ... 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the ... skeletal muscle troponin activator tirasemtiv in the journal ... Phase IIa “Evidence of Effect” or hypothesis-generating clinical ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: